This is a preview of subscription content, log in via an institution to check access.
Notes
2018/2019 British pounds
Reference
Barker J, et al. Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis Clinical Drug Investigation : 16 Oct 2021. Available from: URL: https://doi.org/10.1007/s40261-021-01089-4
Rights and permissions
About this article
Cite this article
Adalimumab biosimilar cost effective first-line treatment for psoriasis. PharmacoEcon Outcomes News 890, 1 (2021). https://doi.org/10.1007/s40274-021-08124-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08124-0